The Rare Neurodegenerative Disease Treatment Market segment is characterized by extreme fragmentation, where the primary delineator is not the clinical diagnosis but the specific genetic mutation or biochemical deficiency driving the disease. Given the precision required for modern therapies, a single clinical condition, such as a form of inherited ataxia, may represent several distinct market...